Cargando…
Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review
Intrahepatic lymphoepithelioma-like cholangiocarcinoma (LELCC) is a very rare malignant tumor arising from the biliary epithelium. To date, there has been a lack of evidence on the radiographical features, clinicopathological features, and treatment modalities of LELCC, with less than 28 cases of LE...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971717/ https://www.ncbi.nlm.nih.gov/pubmed/36865802 http://dx.doi.org/10.3389/fonc.2023.1090580 |
_version_ | 1784898157742653440 |
---|---|
author | Sam Saji, Alen Yang, Biao Hou, Wan Ting Liu, Xia Ren, Qiu Ping Wei, Yuan Feng Zhang, Yu Zu Yang, Xi |
author_facet | Sam Saji, Alen Yang, Biao Hou, Wan Ting Liu, Xia Ren, Qiu Ping Wei, Yuan Feng Zhang, Yu Zu Yang, Xi |
author_sort | Sam Saji, Alen |
collection | PubMed |
description | Intrahepatic lymphoepithelioma-like cholangiocarcinoma (LELCC) is a very rare malignant tumor arising from the biliary epithelium. To date, there has been a lack of evidence on the radiographical features, clinicopathological features, and treatment modalities of LELCC, with less than 28 cases of LELCC without Epstein–Barr virus (EBV) infection having been reported worldwide. The treatment of LELCC remains unexplored. Here, we present two cases of patients with LELCC without EBV infection who were treated by liver resection, chemotherapy, and immunotherapy and who achieved long survival time. The patients received surgery to remove the tumors and then adjuvant chemotherapy using the GS regimen and combined immunotherapy involving natural killer–cytokine-induced killer (NK-CIK) and nivolumab were performed. Both patients had a good prognosis with a survival time of more than 100 months and 85 months. |
format | Online Article Text |
id | pubmed-9971717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99717172023-03-01 Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review Sam Saji, Alen Yang, Biao Hou, Wan Ting Liu, Xia Ren, Qiu Ping Wei, Yuan Feng Zhang, Yu Zu Yang, Xi Front Oncol Oncology Intrahepatic lymphoepithelioma-like cholangiocarcinoma (LELCC) is a very rare malignant tumor arising from the biliary epithelium. To date, there has been a lack of evidence on the radiographical features, clinicopathological features, and treatment modalities of LELCC, with less than 28 cases of LELCC without Epstein–Barr virus (EBV) infection having been reported worldwide. The treatment of LELCC remains unexplored. Here, we present two cases of patients with LELCC without EBV infection who were treated by liver resection, chemotherapy, and immunotherapy and who achieved long survival time. The patients received surgery to remove the tumors and then adjuvant chemotherapy using the GS regimen and combined immunotherapy involving natural killer–cytokine-induced killer (NK-CIK) and nivolumab were performed. Both patients had a good prognosis with a survival time of more than 100 months and 85 months. Frontiers Media S.A. 2023-01-30 /pmc/articles/PMC9971717/ /pubmed/36865802 http://dx.doi.org/10.3389/fonc.2023.1090580 Text en Copyright © 2023 Sam Saji, Yang, Hou, Liu, Ren, Wei, Zhang and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Sam Saji, Alen Yang, Biao Hou, Wan Ting Liu, Xia Ren, Qiu Ping Wei, Yuan Feng Zhang, Yu Zu Yang, Xi Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review |
title | Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review |
title_full | Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review |
title_fullStr | Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review |
title_full_unstemmed | Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review |
title_short | Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review |
title_sort | combined nk-cik and pd-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with ebv infection: two case reports and a literature review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971717/ https://www.ncbi.nlm.nih.gov/pubmed/36865802 http://dx.doi.org/10.3389/fonc.2023.1090580 |
work_keys_str_mv | AT samsajialen combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview AT yangbiao combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview AT houwanting combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview AT liuxia combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview AT renqiuping combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview AT weiyuanfeng combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview AT zhangyuzu combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview AT yangxi combinednkcikandpd1inhibitornivolumabaneffectiveimmunotherapyfortreatingintrahepaticlymphoepitheliomalikecholangiocarcinomaunassociatedwithebvinfectiontwocasereportsandaliteraturereview |